Compare DDS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDS | RNA |
|---|---|---|
| Founded | 1938 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 227.6M |
| IPO Year | N/A | 2025 |
| Metric | DDS | RNA |
|---|---|---|
| Price | $582.23 | $13.75 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $519.67 | $69.26 |
| AVG Volume (30 Days) | 125.1K | ★ 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.06 | $88.12 |
| Revenue Next Year | $2.02 | $18.11 |
| P/E Ratio | $18.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $282.24 | $13.06 |
| 52 Week High | $741.98 | $73.06 |
| Indicator | DDS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 5.62 |
| Support Level | $519.06 | $13.06 |
| Resistance Level | $634.02 | $72.52 |
| Average True Range (ATR) | 25.72 | 0.99 |
| MACD | -3.73 | -2.13 |
| Stochastic Oscillator | 17.00 | 1.21 |
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.